363 related articles for article (PubMed ID: 27696391)
1. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia.
Gómez-Seguí I; Cervera J; Such E; Martínez-Cuadrón D; Luna I; Ibáñez M; López-Pavía M; Gascón A; Roig M; Martínez J; Sanz J; Montesinos P; Martín-Aragonés G; Lorenzo I; Senent L; Barragán E; Cordón L; Sempere A; Sanz GF; Sanz MA
Ann Hematol; 2012 Jan; 91(1):19-25. PubMed ID: 21935650
[TBL] [Abstract][Full Text] [Related]
5. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
[TBL] [Abstract][Full Text] [Related]
6. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Ravandi F; Jorgensen JL; O'Brien SM; Jabbour E; Thomas DA; Borthakur G; Garris R; Huang X; Garcia-Manero G; Burger JA; Ferrajoli A; Wierda W; Kadia T; Jain N; Wang SA; Konoplev S; Kebriaei P; Champlin RE; McCue D; Estrov Z; Cortes JE; Kantarjian HM
Br J Haematol; 2016 Feb; 172(3):392-400. PubMed ID: 26492205
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
10. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
11. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Jabbour EJ; O'Brien SM; Faderl S; Burger JA; Garris R; Qiao W; Huang X; Jain N; Konopleva M; Kadia TM; Daver N; Borthakur G; Cortes JE; Ravandi F
Am J Hematol; 2016 Jun; 91(4):385-9. PubMed ID: 26800008
[TBL] [Abstract][Full Text] [Related]
13. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
15. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
16. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
[TBL] [Abstract][Full Text] [Related]
17. A Single Institution's Experience with Cytogenetic and MRD Outcomes in Pediatric Acute Lymphoblastic Leukemia.
Amjad A; Wali RM; Anjum S; Mansoor R
J Coll Physicians Surg Pak; 2019 Jun; 29(6):549-552. PubMed ID: 31133155
[TBL] [Abstract][Full Text] [Related]
18. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Short NJ; Jabbour E; Sasaki K; Patel K; O'Brien SM; Cortes JE; Garris R; Issa GC; Garcia-Manero G; Luthra R; Thomas D; Kantarjian H; Ravandi F
Blood; 2016 Jul; 128(4):504-7. PubMed ID: 27235138
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
20. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
